Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, single-center, single-arm study evaluating endoscopic ultrasound-guided ethanol ablation for left-sided aldosterone-producing adenoma. Eligible participants will receive the ablation procedure and be followed for safety, imaging response, biochemical remission, and clinical remission. The study is expected to enroll 30 participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Endoscopic Ultrasound-Guided Ethanol Ablation | Experimental | Participants with left-sided unilateral aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Endoscopic Ultrasound-Guided Ethanol Ablation | Procedure | Participants with left-sided aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance. |
| Measure | Description | Time Frame |
|---|---|---|
| Procedure-related major adverse events | Assessment of predefined procedure-related major adverse events occurring within 24-48 hours after endoscopic ultrasound-guided ethanol ablation, including imaging-confirmed major bleeding, gastrointestinal perforation, major organ infarction, and hypertensive urgency or emergency (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHg). | Within 24-48 hours after endoscopic ultrasound-guided ethanol ablation |
| Measure | Description | Time Frame |
|---|---|---|
| Complete tumor ablation on imaging | Complete radiologic ablation will be assessed by PET/CT at 6 months after endoscopic ultrasound-guided ethanol ablation. Complete ablation is defined as no abnormal radiotracer uptake in the treated adrenal lesion. | 6 months after endoscopic ultrasound-guided ethanol ablation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shumin Yang, MD, PhD | Contact | +86-023-89011552 | ysm@hospital.cqmu.edu.cn | |
| Liang Deng, MD, PhD | Contact | +86-023-89011510 | dengliang@hospital.cqmu.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Shumin Yang, MD, PhD | First Affiliated Hospital of Chongqing Medical University | Principal Investigator |
| Liang Deng, MD, PhD | First Affiliated Hospital of Chongqing Medical University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Chongqing Medical University | Chongqing | Choongqing | 400016 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42276127 | Result | Deng L, Hao Y, Zhang X, Li Q, Hu J, Yang S. Endoscopic ultrasound-guided ethanol ablation for aldosterone-producing adenoma. Endoscopy. 2026 Jun;58(S 02):E702-E703. doi: 10.1055/a-2875-0099. Epub 2026 Jun 11. No abstract available. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Individual participant data (IPD) will not be made publicly available.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006929 | Hyperaldosteronism |
| D018246 | Adrenocortical Adenoma |
| ID | Term |
|---|---|
| D000308 | Adrenocortical Hyperfunction |
| D000307 | Adrenal Gland Diseases |
| D004700 | Endocrine System Diseases |
| D000306 | Adrenal Cortex Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Complete biochemical remission rate |
The proportion of participants with complete biochemical remission at 6 months after endoscopic ultrasound-guided ethanol ablation will be assessed according to the PASO consensus criteria. Complete biochemical remission is defined as normalization of serum potassium and aldosterone-to-renin ratio, or normalization of serum potassium with suppressed aldosterone secretion on confirmatory testing, defined as post-SSIT aldosterone <80 pg/mL or post-CCT aldosterone <110 pg/mL. |
| 6 months after endoscopic ultrasound-guided ethanol ablation |
| Complete clinical remission rate | The proportion of participants with complete clinical remission at 6 months after endoscopic ultrasound-guided ethanol ablation will be assessed according to the PASO consensus criteria. Complete clinical remission is defined as normal blood pressure without any antihypertensive medication. | 6 months after endoscopic ultrasound-guided ethanol ablation |
| D000310 | Adrenal Gland Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D000303 | Adrenal Cortex Diseases |